CRA was retained by a pharmaceutical company to assist in settlement negotiations with a potential generic competitor. As part of this project, CRA prepared a flexible valuation model to estimate the expected profits from the perspective of the generic competitor under various assumptions. CRA also prepared a decision probability tree analysis to address issues related to litigation risk, acceptable date of generic entry and the impact of an authorized generic.
Update on the newly established Texas Business Court
On September 1, 2024, the Texas Business Court became officially operational, following Governor Greg Abbott’s signing of House Bill 19 in 2023 to create the...